Zobrazeno 1 - 4
of 4
pro vyhledávání: '"André, Manica"'
Autor:
André Manica, Rogério Sarmento-Leite, Clara Manfroi, La Hore Rodrigues Jr, Carlos Gottschall, Julio F Marchini, Kevin Croce
Publikováno v:
Arquivos Brasileiros de Cardiologia, Vol 100, Iss 1, Pp 29-36 (2013)
FUNDAMENTO: A aspirina (Ácido Acetilsalicílico - AAS) é capaz de reduzir eventos adversos cardiovasculares em pacientes portadores de Doença Arterial Coronariana (DAC) através da inibição da atividade plaquetária. Alguns pacientes com DAC, ap
Externí odkaz:
https://doaj.org/article/7724b922d52b49b497bb2b49069d395a
Autor:
André Manica, Rogerio Sarmento Leite, Beatriz D'Agord Schaan, P. Reed Larsen, Josi Vidart, Simone Magagnin Wajner, Ana Luiza Maia
Publikováno v:
The Journal of Clinical Endocrinology & Metabolism. 99:4537-4545
The acute phase of the nonthyroidal illness syndrome (NTIS) is characterized by low T3 and high rT3 levels, affecting up to 75% of critically ill patients. Oxidative stress has been implicated as a causative factor of the disturbed peripheral thyroid
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c75252b15f8994c3825f2f6a5a6ce59
https://doi.org/10.1210/jc.2014-2192
https://doi.org/10.1210/jc.2014-2192
Autor:
André Manica, Rogério Sarmento-Leite, Clara Manfroi, La Hore Rodrigues Jr, Carlos Gottschall, Julio F Marchini, Kevin Croce
Publikováno v:
Arquivos Brasileiros de Cardiologia, Vol 100, Iss 1, Pp 29-36
FUNDAMENTO: A aspirina (Ácido Acetilsalicílico - AAS) é capaz de reduzir eventos adversos cardiovasculares em pacientes portadores de Doença Arterial Coronariana (DAC) através da inibição da atividade plaquetária. Alguns pacientes com DAC, ap
Externí odkaz:
https://doaj.org/article/0618bdaf2730486dbaa50f1a88cb0af5
Prevalence of high platelet reactivity in aspirin-treated patients referred for coronary angiography
Autor:
André, Manica, Rogério, Sarmento-Leite, Clara, Manfroi, La Hore, Rodrigues, Carlos, Gottschall, Julio F, Marchini, Kevin, Croce
Publikováno v:
Arquivos brasileiros de cardiologia. 100(1)
Aspirin (ASA) reduces adverse events in coronary artery disease (CAD) patients by inhibiting platelets. Some CAD patients have high platelet reactivity (HPR) despite ASA therapy and these individuals have increased risk of adverse events.The purpose
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::a453f9ee2a03938b7a387014500ddb75
https://pubmed.ncbi.nlm.nih.gov/23295251
https://pubmed.ncbi.nlm.nih.gov/23295251